{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:30:35Z","timestamp":1772641835646,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1038\/s41375-023-02081-x","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T11:02:17Z","timestamp":1699614137000},"page":"207-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9701-1851","authenticated-orcid":false,"given":"Tomas","family":"Radivoyevitch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt E.","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"2081_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107:185\u201393.","journal-title":"Int J Hematol"},{"key":"2081_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","volume":"35","author":"YC Hsieh","year":"2021","unstructured":"Hsieh YC, Kirschner K, Copland M. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia. 2021;35:1229\u201342.","journal-title":"Leukemia"},{"key":"2081_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.leukres.2017.03.003","volume":"57","author":"RP Gale","year":"2017","unstructured":"Gale RP, Opelz G. Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much. Leuk Res. 2017;57:109\u201311.","journal-title":"Leuk Res"},{"key":"2081_CR4","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/0008-5472.CAN-19-2175","volume":"80","author":"T Hahnel","year":"2020","unstructured":"Hahnel T, Baldow C, Guilhot J, Guilhot F, Saussele S, Mustjoki S, et al. Model-based inference and classification of immunologic control mechanisms from TKI cessation and dose reduction in patients with CML. Cancer Res. 2020;80:2394\u2013406.","journal-title":"Cancer Res"},{"key":"2081_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.leukres.2019.02.003","volume":"79","author":"T Radivoyevitch","year":"2019","unstructured":"Radivoyevitch T, Jorgensen TN, Lindner DJ, Maciejewski JP, Miyazaki Y, Gale RP. Chronic myeloid leukemia: Two mysteries. Leuk Res. 2019;79:3\u20135.","journal-title":"Leuk Res"},{"key":"2081_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cellimm.2015.02.001","volume":"294","author":"TN Jorgensen","year":"2015","unstructured":"Jorgensen TN. Sex disparities in the immune response. Cell Immunol. 2015;294:61\u20132.","journal-title":"Cell Immunol"},{"key":"2081_CR7","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1080\/21645515.2018.1462639","volume":"14","author":"JD Allen","year":"2018","unstructured":"Allen JD, Ross TM. H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation. Hum Vaccin Immunother. 2018;14:1840\u201347.","journal-title":"Hum Vaccin Immunother"},{"key":"2081_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00411-020-00879-2","volume":"60","author":"T Radivoyevitch","year":"2021","unstructured":"Radivoyevitch T. Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries. Radiat Environ Biophys. 2021;60:41\u20137.","journal-title":"Radiat Environ Biophys"},{"key":"2081_CR9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.celrep.2016.09.068","volume":"17","author":"FJ Kohlhapp","year":"2016","unstructured":"Kohlhapp FJ, Huelsmann EJ, Lacek AT, Schenkel JM, Lusciks J, Broucek JR, et al. Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death. Cell Rep. 2016;17:957\u201365.","journal-title":"Cell Rep"},{"key":"2081_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-2-27","volume":"2","author":"M Matsuoka","year":"2005","unstructured":"Matsuoka M. Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology. 2005;2:27.","journal-title":"Retrovirology"},{"key":"2081_CR11","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41375-021-01272-8","volume":"35","author":"M Baccarani","year":"2021","unstructured":"Baccarani M, Gale RP. Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors. Leukemia. 2021;35:2199\u2013204.","journal-title":"Leukemia"},{"key":"2081_CR12","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41375-019-0647-x","volume":"34","author":"IS Pagani","year":"2020","unstructured":"Pagani IS, Dang P, Saunders VA, Grose R, Shanmuganathan N, Kok CH, et al. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia. 2020;34:1052\u201361.","journal-title":"Leukemia"},{"key":"2081_CR13","doi-asserted-by":"publisher","first-page":"e0008361","DOI":"10.1371\/journal.pntd.0008361","volume":"14","author":"D Kodama","year":"2020","unstructured":"Kodama D, Tanaka M, Matsuzaki T, Izumo K, Nakano N, Matsuura E, et al. Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy\/tropical spastic paraparesis. PLoS Negl Trop Dis. 2020;14:e0008361.","journal-title":"PLoS Negl Trop Dis"},{"key":"2081_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41375-019-0699-y","volume":"34","author":"T Radivoyevitch","year":"2020","unstructured":"Radivoyevitch T, Weaver D, Hobbs B, Maciejewski JP, Hehlmann R, Jiang Q, et al. Do persons with chronic myeloid leukaemia have normal or near normal survival? Leukemia. 2020;34:333\u20135.","journal-title":"Leukemia"},{"key":"2081_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41375-019-0679-2","volume":"34","author":"T Ernst","year":"2020","unstructured":"Ernst T, Rinke J, Hagen J, Dmytrenko I, Hochhaus A, Dyagil I. Molecular-defined clonal evolution in patients with chronic myeloid leukemia who were exposed to ionizing radiation following the Chernobyl nuclear disaster. Leukemia. 2020;34:645\u201350.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02081-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02081-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02081-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:06:00Z","timestamp":1704809160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02081-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2081"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02081-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a consultant to Antengene Biotech LLC; Medical Director, FFF Enterprises Inc.; A speaker for Janssen Pharma and Hengrui Pharma; Board of Directors: Russian Foundation for Cancer Research Support and Scientific Advisory Board, StemRad Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}